These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31503216)

  • 21. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
    Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
    Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
    Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
    J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab.
    Rissel F; Cazaubon Y; Saffar S; Altwegg R; Artasone M; Lozano C; Vincent T; Jentzer A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.
    Grossberg LB; Papamichael K; Feuerstein JD; Siegel CA; Ullman TA; Cheifetz AS
    Inflamm Bowel Dis; 2017 Dec; 24(1):191-197. PubMed ID: 29272486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
    Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
    Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of strategies to suppress antibodies to infliximab in pediatric inflammatory bowel disease.
    Jagt JZ; Holleman KW; Benninga MA; Van Limbergen JE; de Boer NKH; de Meij TGJ
    J Pediatr Gastroenterol Nutr; 2024 Jan; 78(1):57-67. PubMed ID: 38291692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.
    van Hoeve K; Hoffman I; Vermeire S
    Expert Opin Drug Saf; 2018 Feb; 17(2):185-196. PubMed ID: 29202588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.
    Papamichael K; Vogelzang EH; Lambert J; Wolbink G; Cheifetz AS
    Expert Rev Clin Immunol; 2019 Aug; 15(8):837-848. PubMed ID: 31180729
    [No Abstract]   [Full Text] [Related]  

  • 30. Advantages of Proactive Therapeutic Drug Monitoring in a Prospective Cohort of Children With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor.
    Gasparetto M; Burgess N; Naik S; Studart D; Kadir A; Croft N; Sanderson I; Deb P
    J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):484-489. PubMed ID: 35129158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of proactive drug monitoring in inflammatory bowel disease treated with anti-TNF agents: A systematic review and meta-analysis.
    Manceñido Marcos N; Novella Arribas B; Mora Navarro G; Rodríguez Salvanés F; Loeches Belinchón P; Gisbert JP
    Dig Liver Dis; 2024 Mar; 56(3):421-428. PubMed ID: 37422409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Vitamin D on Response to Anti-tumor Necrosis Factor-α Therapy in Children With Inflammatory Bowel Disease.
    Hizarcioglu-Gulsen H; Kaplan JL; Moran CJ; Israel EJ; Lee H; Winter H
    J Pediatr Gastroenterol Nutr; 2021 May; 72(5):e125-e131. PubMed ID: 33847289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis.
    Hu Y; Song Z; Gao Y; Jiang D; Ran Y; Ma Y; Li H; Zhao R
    Expert Rev Clin Pharmacol; 2024 Oct; 17(10):935-948. PubMed ID: 39417358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.
    Stallhofer J; Guse J; Kesselmeier M; Grunert PC; Lange K; Stalmann R; Eckardt V; Stallmach A
    Int J Colorectal Dis; 2023 Feb; 38(1):54. PubMed ID: 36840779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing.
    Keating PE; Hock BD; Smith SM; Chin PKL; O'Donnell JL; Barclay ML
    Intern Med J; 2023 Nov; 53(11):2123-2127. PubMed ID: 37997271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-Tumor Necrosis Factor Alpha Therapeutic Drug Monitoring in Inflammatory Disease: A Systematic Review.
    Schneider C; Stratman S; Choragudi S; Lev-Tov H
    J Drugs Dermatol; 2023 May; 22(5):445-450. PubMed ID: 37133467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study.
    Fuentes-Valenzuela E; García-Alonso FJ; Maroto-Martín C; Juan Casamayor L; Garrote JA; Almendros Muñoz R; De Prado Á; Vara Castrodeza A; Marinero MÁ; Calleja Carbajosa R; Barrio J
    Inflamm Bowel Dis; 2023 Oct; 29(10):1586-1593. PubMed ID: 36617284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.
    Strik AS; Bots SJ; D'Haens G; Löwenberg M
    Expert Rev Clin Pharmacol; 2016; 9(3):429-39. PubMed ID: 26681400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients.
    Colman RJ; Portocarrero-Castillo A; Chona D; Hellmann J; Minar P; Rosen MJ
    Inflamm Bowel Dis; 2021 Mar; 27(4):507-515. PubMed ID: 32426829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.